RxDoctor Payments Data

Stephen Brown, MD

Colon & Rectal Surgery · Phoenix, AZNPI 1558358275

Payments from drug & device makers

What this record shows

21 manufacturers reported payments, led by AbbVie at 31.7% of the total. Reporting peaked in 2020 at $1,624 and has fallen 80.8% since, to $312 in 2025. That places this record below the midpoint for colon & rectal surgery clinicians in AZ, where the typical reported total is $5,787.

$2,842in general payments, 2019–2025

Across 42 payments — averaging $67.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$900
  • Intuitive Surgical$733
  • Takeda Pharmaceuticals U.S.A., Inc.$223
  • Medtronic$208
  • Davol Inc.$194
  • Boston Scientific$89
  • plus $494 from 15 others

What the payments were for

  • Consulting fees$1,15341%
  • Food & beverage$1,68859%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,842 in reported general payments places this provider in the 30th percentile of 50 colon & rectal surgery providers in Arizona.

See all colon & rectal surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$66,086
Medicare patients
176
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide17$14,554
Colesevelam Hcl13$4,074
Oxycodone Hcl35$305
Neomycin Sulfate19$100
Metronidazole21$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$900$14,55417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 50 colon & rectal surgery providers in Arizona.

Other colon & rectal surgery in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →